Relypsa, Inc. has reported positive results on both the primary and secondary efficacy endpoints in a trial of patiromer for the treatment of hyperkalemia. The results cover Part B, the placebo-controlled randomized withdrawal portion of its two-part Phase III trial. The results demonstrate that, after having treated hyperkalemia and controlled serum potassium in the treatment phase (Part A) of the trial, hyperkalemia recurred at any time during Part B in significantly more subjects randomized ...